New studies show malaria vaccine candidate advancing in Africa
Monday, December 8, 2008 - 12:49
in Health & Medicine
Results published online today in the New England Journal of Medicine revealed that the world's most clinically advanced malaria vaccine candidate provides both infants and young children with significant protection against malaria. Two separate phase II trials reaffirmed earlier study results and support the ongoing efforts, pending regulatory approvals, to launch the phase III study of GlaxoSmithKline (GSK) Biologicals' RTS,S/AS vaccine candidate across Africa.
Read the whole article on Physorg
More from Physorg
Related
- Promising trials of malaria vaccine lead to calls for Phase 3 developmentMon, 8 Dec 2008, 12:32:14 EST
- India continues to progress in AIDS vaccine development effortsMon, 18 Aug 2008, 0:22:02 EDT
- Results of landmark study of HIV vaccine published in the LancetWed, 12 Nov 2008, 18:42:45 EST
- IAVI statement in response to NIAID decision not to move forward with PAVE 100 HIV Vaccine TrialThu, 17 Jul 2008, 12:14:46 EDT
- UM School of Medicine researchers find extreme genetic variability in malaria parasiteWed, 14 Oct 2009, 15:00:37 EDT